Antibe Therapeutics Reports Q1 2018 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE) (OTCQX:ATBPF) filed its financial and operating results on Tuesday, August
29th for the fiscal quarter ended June 30, 2017. The Corporation’s unaudited fiscal Q1 2018 condensed interim
consolidated financial statements and MD&A are available on SEDAR.
Dan Legault, Antibe’s CEO, commented, “The successful completion of our brokered financing was a significant achievement this
quarter, raising $5 million in gross proceeds that fully funds the key Phase 2b GI safety study designed to demonstrate
best-in-class status of our lead drug, ATB-346. This clinical trial was approved by Health Canada earlier this month and is
actively recruiting subjects, with a data read-out anticipated in Q1 2018. Finally, Citagenix has been making progress on brand
strategy and technology initiatives to support its global growth strategy during a seasonally quiet period.”
Q1 2018 Highlights
- Strengthened balance sheet with the successful completion of the first closing of a brokered
prospectus offering (the “Offering”) raising gross proceeds of $4,050,000;
- Engagement of Topstone Research Inc. (“Topstone”) to manage the recently commenced Phase 2 GI safety
study for lead drug, ATB-346;
- Retention of Dr. Francis Chan, a leading gastroenterologist with extensive NSAID clinical trial
expertise, as a key advisor in the Phase 2 GI safety study for ATB-346; and
- Formal commencement of Investigational New Drug (“IND”) enabling pre-clinical studies for its second
pipeline drug, ATB-352, a non-addictive, potent analgesic for the treatment of severe pain.
Post Q1 2018 Highlights
- Received approval from Health Canada in early August to initiate a Phase 2, double-blind, GI
endoscopy trial for lead drug, ATB-346; and
- Successfully completed the second and final closing of the Offering for additional gross proceeds of
$933,000, for combined total gross proceeds of $4,983,000 raised under the Offering.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing
molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug, ATB-346, targets the global need for a
safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent
global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin.
www.antibethera.com.
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products
servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of
knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries,
operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com.
Forward Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the growth of product
sales, engaging new distributors and independent representatives and the licensing and development of drugs and medical devices.
Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those
identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", "propose" and similar
expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results,
performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause
actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s
ability to secure additional financing, its ability to execute its business strategy and successfully compete in the market, and
risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the
forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking
statements except as required by applicable law.
Antibe Therapeutics Inc.
Dan Legault, 416-473-4095
Chief Executive Officer
dan.legault@antibethera.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170829006236/en/